Elevated plasma pentraxin 3: A potential cardiovascular risk factor?

Medical Hypotheses

Volumn 77, Issue 6, 2011, Pages 1068-1070

  Liu, Qiming ^a   Tu, Tao ^a   Bai, Zhongle ^a   Liu, Zhenjiang ^a   Zhou, Shenghua ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PENTRAXIN 3;

ADVERSE OUTCOME; ANGIOGENESIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE COURSE; HUMAN; ISCHEMIC HEART DISEASE; MULTICENTER STUDY; PROTEIN EXPRESSION; RESTENOSIS; RISK FACTOR;

ANGIOGENESIS INHIBITORS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; MODELS, BIOLOGICAL; MYOCARDIAL ISCHEMIA; RISK FACTORS; SERUM AMYLOID P-COMPONENT;

EID: 80755132230     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.09.004     Document Type: Article

References (33)

1. Véronique L.R., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
2. Jakubowski H. Pathophysiological consequences of homocysteine excess. J Nutr 2006, 136:1741S-1749S.
3. Peri G., Introna M., Corradi D., et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000, 102:636-641.
4. Latini R., Maggioni A.P., Peri G., et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004, 110:2349-2354.
5. Matsui S., Ishii J., Kitagawa F., et al. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 2010, 210:220-225.
6. Suzuki S., Takeishi Y., Niizeki T., et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008, 155:75-81.
7. Kotooka N., Inoue T., Aoki S., Anan M., Komoda H., Node K. Prognostic value of pentraxin 3 in patients with chronic heart failure. Int J Cardiol 2008, 130:19-22.
8. Jylhävä J., Haarala A., Kähönen M., et al. Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clin Exp Immunol 2011, 164:211-217.
9. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
10. Lundberg A.M., Hansson G.K. Innate immune signals in atherosclerosis. Clin Immunol 2010, 134:5-24.
11. Mann D.L. Tumor necrosis factor and viral myocarditis: the fine line between innate and inappropriate immune responses in the heart. Circulation 2001, 103:626-629.
12. Mann D.L. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 2003, 65:81-101.
13. Mann D.L., Topkara V.K., Evans S., Barqer P.M. Innate immunity in the adult mammalian heart: for whom the cell tolls. Trans Am Clin Climatol Assoc 2010, 121:34-50.
14. Deban L., Jaillon S., Garlanda C., Bottazzi B., Mantovani A. Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res 2011, 343:237-249.
15. Inforzato A., Jaillon S., Moallie F., et al. The long pentraxin PTX3 at the crossroads between innate immunity and tissue remodeling. Tissue Antigens 2011, 77:271-282.
16. Bottazzi B., Garlanda C., Cotena A., et al. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev 2009, 227:9-18.
17. Dong Z., An F., Wu T., et al. PTX3, a key component of innate immunity, is induced by SAA via FPRL1-mediated signaling in HAECs. J Cell Biochem 2011, 112:2097-2105.
18. Rusnati M., Camozzi M., Moroni E., et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004, 104:92-99.
19. Presta M., Camozzi M., Salvatori G., Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med 2007, 11:723-738.
20. Camozzi M., Zacchigna S., Rusnati M., et al. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol 2005, 25:1837-1842.
21. Norata G.D., Garlanda C., Catapano A.L. The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 2010, 20:35-40.
22. Rolph M.S., Zimmer S., Bottazzi B., Garlanda C., Mantovani A., Hansson G.K. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002, 22:e10-14.
23. Savchenko A., Imamura M., Ohashi R., et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008, 215:48-55.
24. Matsubara J., Sugiyama S., Nozaki T., et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 2011, 57:861-869.
25. Jenny N.S., Arnold A.M., Kuller L.H., Tracy R.P., Psaty B.M. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2009, 29:594-599.
26. Zanetti M., Bosutti A., Ferreira C., et al. Circulating pentraxin 3 levels are higher in metabolic syndrome with subclinical atherosclerosis: evidence for association with atherogenic lipid profile. Clin Exp Med 2009, 9:243-248.
27. Yamasaki K., Kurimura M., Kasai T., et al. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med 2009, 47:471-477.
28. Hollan I., Bottazzi B., Cuccovillo I., et al. Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. Arthritis Care Res (Hoboken) 2010, 62:378-385.
29. Alberti L., Gilardini L., Zulian A., et al. Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis 2009, 202:455-460.
30. Bosutti A., Grassi G., Zanetti M., et al. Relation between the plasma levels of LDL-cholesterol and the expression of the early marker of inflammation long pentraxin PTX3 and the stress response gene p66ShcA in pacemaker-implanted patients. Clin Exp Med 2007, 7:16-23.
31. Salio M., Chimenti S., De Angelis N., et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008, 117:1055-1064.
32. Norata G.D., Marchesi P., Pulakazhi Venu V.K., et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009, 120:699-708.
33. Deban L., Russo R.C., Sironi M., et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol 2010, 11:328-334.